Corticosteroids/β2-agonists in Hair in Asthmatic Patients (CorticHair) (CorticHair)
Asthma
About this trial
This is an interventional other trial for Asthma
Eligibility Criteria
Inclusion Criteria:
- Provision of informed consent prior to any study specific procedure
- Outpatients with asthma, of either gender, aged ≥18 and <50 years at visit 1
- Controlled or partly controlled asthma according to the Global Initiative for Asthma (GINA) guideline
- Receiving a constant daily dose ≥400 µg budesonide of budesonide/formoterol Turbuhaler® for more than 2 months
- No treatment step-down is planned in the 3 next months
- ACQ (Asthma Control Questionnaire) score ≤ 1.50
- Patient with healthcare insurance
Exclusion Criteria:
- Pregnant women or women wishing to become pregnant in the next 3 months
- Patients with body mass index (BMI) <18 or >30
- Patients with known kidney or liver disease (creatinine clearance < 60 mL/min/1.73 m² or alanine aminotransferase (ALAT) > 5N)
- Smokers or former smokers < 3 years
- Patients with simultaneous asthma and chronic obstructive pulmonary disease (COPD) (or defined as having asthma-COPD overlap syndrome)
- Other budesonide- or formoterol-containing drugs (e.g Foradil®, Rhinocort®, Mikicort®, Entocort®…)
- CYP3A4 inducers (systemic corticosteroid, rifampicin, phenobarbital, carbamazepine…)
- CYP3A4 inhibitors (macrolides, azole antifungals, valproic acid, amiodarone, fluoxetine)
- Hair treatment (coloration, bleaching, perming…)
- Hairless patients, hair implants or hair extensions
- Length of hair from the vertex posterior region < 5 cm or planning to cut hair from this region shorter than 5 cm in the next 4 months
- Patient deprived of liberty by judicial or administrative decision
- Major protected by law
Sites / Locations
- Foch Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Medium dose of Symbicort Turbuhaler®
High dose of Symbicort Turbuhaler®
The population is asthmatic patients meeting the inclusion and exclusion criteria for whom the optimized total daily dose to treat the disease is ≥400 to 800 µg budesonide of budesonide/formoterol Symbicort Turbuhaler®. Hair sampling after 4 months treatment. Analysis of hair's drug concentrations.
The population is asthmatic patients meeting the inclusion and exclusion criteria for whom the optimized total daily dose to treat the disease is ≥800 µg budesonide of budesonide/formoterol Symbicort TurbuhalerTurbuhaler®. Hair sampling after 4 months treatment. Analysis of hair's drug concentrations.